G1 Therapeutics (NASDAQ:GTHX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research note published on Wednesday, Benzinga reports. They currently have a $12.00 price target on the stock.

Several other equities research analysts have also recently weighed in on GTHX. Wedbush reaffirmed an outperform rating and issued a $5.00 price target (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. HC Wainwright reaffirmed a buy rating and issued a $9.00 price target on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Price Performance

G1 Therapeutics stock opened at $4.31 on Wednesday. The firm has a 50-day moving average of $4.26 and a two-hundred day moving average of $3.37. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $6.14. The stock has a market cap of $225.33 million, a price-to-earnings ratio of -6.95 and a beta of 1.71. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.94 and a quick ratio of 2.55.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The business had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.21 million. During the same period in the previous year, the company posted ($0.53) EPS. On average, research analysts forecast that G1 Therapeutics will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Financial Advocates Investment Management bought a new position in shares of G1 Therapeutics during the 4th quarter worth approximately $39,000. SG Americas Securities LLC acquired a new position in G1 Therapeutics during the 1st quarter valued at approximately $58,000. Capstone Investment Advisors LLC acquired a new position in G1 Therapeutics during the 4th quarter valued at approximately $76,000. Jump Financial LLC acquired a new position in G1 Therapeutics during the 4th quarter valued at approximately $105,000. Finally, Choreo LLC acquired a new position in G1 Therapeutics during the 4th quarter valued at approximately $107,000. Institutional investors own 24.21% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.